Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12157715 | 0.88 | SCN9A (0.76) | SCN9A | |
| SCHEMBL3606389 | 0.84 | SCN9A (1.00) | SCN9A | |
| SCHEMBL3589126 | 0.82 | SCN9A (1.00) | SCN9A | |
| SCHEMBL3468414 | 0.80 | SCN9A (0.47) | SCN9A | |
| SCHEMBL3328634 | 0.79 | SCN9A (0.75) | SCN9A | |
| SCHEMBL3329179 | 0.79 | SCN9A (0.84) | SCN9A | |
| SCHEMBL18215662 | 0.79 | SCN9A (0.90) | SCN9A | |
| SCHEMBL1612449 | 0.79 | SCN9A (1.00) | SCN9A | |
| SCHEMBL12314757 | 0.79 | SCN9A (1.00) | SCN9A | |
| SCHEMBL1613112 | 0.79 | SCN9A (1.00) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2011-11-03 | — | — | US | claimed |
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2011-11-03 | — | — | US | disclosed |
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2011-11-03 | — | — | US | disclosed |
| WO-2010078307-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | SCN3A, SCN1B, SCN2B | SCN9A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.